Opinion|Videos|January 21, 2025
Transplant-Ineligible NDMM: Updates from CEPHEUS and IMROZ at ASH 2024
Panelists discuss recent data updates on transplant-ineligible and deferred newly diagnosed multiple myeloma (NDMM), including findings from the CEPHEUS and IMROZ studies, and explore the clinical significance of minimal residual disease negativity as a prognostic and actionable factor in treatment decision-making for NDMM.
Advertisement
Video content above is prompted by the following:
- Please comment on recent data updates for transplant-ineligible/deferred newly diagnosed multiple myeloma (NDMM):
- CEPHEUS study, SubQ Dara-VRd vs VRd in transplant-ineligible NDMM
- IMROZ study, Isa-VRd vs VRd in TIE/deferred NDMM
- What is the clinical significance of minimal residual disease (MRD) negativity as a clinical outcome? How do you interpret and integrate MRD negativity into your clinical decision-making? Beyond its prognostic value, what actionable insights does MRD provide in guiding treatment strategies and patient management?
- Please highlight key insights from MRD analyses in NDMM presented at ASH 2024.
Advertisement
Related to this article
Mary Jo Lechowicz, MD, discussed how pre-transplant depth of response informs the choice between autologous and allogeneic HSCT in T-cell lymphoma.
Jasmine Zain, MD, described the molecular workup to determine whether a secondary malignancy after CAR T-cell therapy reflects direct insertional mutagenesis.
SOHO 2026 sessions covered chemoimmunotherapy in frontline DLBCL, treatment selection via molecular classifiers, and bispecific antibodies for unfit patients.
The FDA cleared the Triton 1 robotic endoscopy system for diagnostic and therapeutic procedures such as colorectal cancer screening and lesion removal.
ASTRO’s first standalone clinical practice guideline for bladder cancer recommends trimodal therapy vs radical cystectomy for select muscle-invasive disease cases.
Investigators are evaluating cesalatamig among patients with advanced cancer in the international phase 1/2 BiPAVE-001 trial.
The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.
Based on updated data from the TRUST-1 trial, a sNDA for taletrectinib has been approved by the FDA for patients with TKI-naive ROS1+ NSCLC.
Advertisement
Advertisement
Trending on CancerNetwork
1
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
2
FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC
3
SOHO 2026: Key Updates Across the Multiple Myeloma Continuum
4
PALOMA-2 Shows Improved Survival vs Historical IV Amivantamab Data
5